论文部分内容阅读
慢性髓系白血病(CML)是一种血液系统造血干细胞恶性增殖性疾病,其一线治疗方案是给予靶向性药物酪氨酸激酶抑制剂(TKI)治疗。虽然TKI治疗CML已取得很大成功,但部分患者由于TKI耐药导致治疗失败。间充质干细胞(MSC)是骨髓微环境内除HSC外的另一种干细胞,具有自
Chronic myeloid leukemia (CML) is a hematopoietic stem cell malignant proliferative disease of the hematopoietic lineage. Its first-line treatment regimen is targeted drug tyrosine kinase inhibitor (TKI) treatment. Although TKI has achieved great success in treating CML, some patients have failed treatment due to TKI resistance. Mesenchymal stem cells (MSCs) are another kind of stem cells in the bone marrow microenvironment except HSC,